Prandin
Benefit of Prandin
You can manage your blood sugar levels with the aid of prandin. By encouraging your body to produce more insulin, it achieves this.
A hormone called insulin aids in the body's use of glucose (sugar) as fuel. Additionally, it aids in the body's storage of glucose. Insulin aids in lowering blood sugar levels when they are too high.
Side effects of Prandin may include
• Hypoglycemia, or low blood sugar.
• jittery or anxious feelings
• Perspiring
• Unsteadiness
• Migraine
• Acid reflux or indigestion
• vomiting
• Constipation
Stop taking Prandin and consult your doctor if you experience any of these side effects.
Please consult your physician, pharmacist, or other healthcare professional if you have any questions about Prandin.
Prandin is not a treatment for diabetes, but it may help you maintain control of your blood sugar levels. While taking this medication, it's crucial to keep up a healthy diet and exercise routine.
How does Prandin work?
Prandin stimulates the body to produce more insulin, which is how it works. A hormone called insulin aids in the body's use of glucose (sugar) as fuel. Additionally, it aids in the body's storage of glucose. Insulin aids in lowering blood sugar levels when they are too high.
Prandin is a diabetes medication that can be used alone or in combination with other drugs like metformin, sulfonylureas, or thiazolidinediones.
Please consult your physician, pharmacist, or other healthcare professional if you have any questions about Prandin.
Prandin is an oral diabetes medication that stimulates the body to regulate blood sugar levels.
Pharmacokinetics
Repaglinide's pharmacokinetics have been examined in both NIDDM patients and healthy adult volunteers. Repaglinide is quickly absorbed from the gastrointestinal tract after oral administration and goes through a significant first-pass metabolism in the liver. Repaglinide's peak plasma concentrations (Cmax) are attained about an hour (max) after a single oral dose. 11 L is the average apparent volume of distribution (V/F). About 98% of plasma proteins bind to them.
Repaglinide excretes from plasma in two phases, the first of which is rapid and the second of which is slower. In the rapid phase, the mean apparent clearance (CL/F) is 131 mL/min, whereas in the slow phase, it is 4.7 mL/min. The average length of stay (MRT) is 3.3 hours.
Following oral administration of 14C-labeled repaglinide to healthy volunteers, over the course of 120 hours, approximately 61% of the dose was recovered in the urine and 39% in the feces. Faecal excretion contained both unchanged drugs and metabolites while urinary excretion mainly consisted of metabolites. Less than 0.1 percent of the dose was excreted in the urine unaltered.
Special Populations
Geriatric Patients: Repaglinide's elimination half-life was longer in a study of 11 elderly NIDDM patients (patients over 65 years old), with a mean value of 7.2 hours compared to 3.3 hours in patients between the ages of 18 and 54. In this study, the geriatric patients' CL/F was decreased and their V/F was raised. The dosage for elderly NIDDM patients does not need to be changed.
Hepatic Impairment: After a single 0.5 mg oral dose, the pharmacokinetics of repaglinide were assessed in 8 subjects with mild (n = 4) and moderate (n = 4) hepatic impairment. Subjects with mild hepatic impairment had Cmax and AUC that were about 2-fold higher than those in healthy subjects, but there was no discernible change in Cmax. Cmax was three times higher, Tmax was prolonged, and AUC was five times higher in subjects with moderate hepatic impairment than in healthy subjects. Both mild and moderate hepatic impairment led to a 50% reduction in the mean apparent clearance (CL/F).
For patients with mild hepatic impairment, there is no need to change the dosage. The starting dose for patients with moderate hepatic impairment should be 0.5 mg once daily.
Renal Impairment: As renal function declined, there was a decrease in the apparent clearance (CL/F) of repaglinide and an increase in the AUC in a study of 8 NIDDM patients with varying levels of renal function (creatinine clearance ranging from 22 to 78 mL/min).
For patients with mild to moderate renal impairment (creatinine clearance 30 mL/min), there is no need to change the dosage. starting dose should be 0.5 mg once daily for patients with severe renal impairment (creatinine clearance 30 mL/min). Repaglinide dosage adjustments should be made in accordance with the patient's response, which should be closely monitored.
Drug Interactions: In vitro research indicates that repaglinide is a cytochrome P450 3A4 (CYP3A4) substrate. Ketoconazole, a CYP3A4 inhibitor, was administered concurrently with repaglinide, which caused its AUC and Cmax to increase by twofold. The pharmacokinetics of repaglinide were unaffected when it was co-administered with gemfibrozil, another CYP3A4 inhibitor.
The pharmacokinetics of repaglinide were unaffected by the coadministration of repaglinide (0.5 mg single dose) and the gastric acid secretion inhibitor cimetidine (800 mg single dose).
Repaglinide is not an inhibitor of the cytochrome P450 isozymes 1A2, 2C9, 2C19, 2D6, or 3A4 according to in vitro data.
Repaglinide does not appear to induce the cytochrome P450 isozymes 1A2, 2B1, 2C9, or 3A4 according to in vitro data.
Following single-dose administration of metformin hydrochloride (500 mg) and repaglinide (0.5 mg) to healthy volunteers, repaglinide had no effect on the pharmacokinetics of metformin.
Following single-dose administration of glipizide (10 mg) and repaglinide (0.5 mg) to healthy volunteers, repaglinide had no effect on the pharmacokinetics of glipizide.